STING Agonist Compounds Resisting Viral Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists have shown limited efficacy in clinical trials for treating diseases and disorders mediated by STING, such as cancer, due to viral suppression mechanisms and poor anti-tumor activity.
Innovation Solution
Development of novel compounds and conjugates that act as STING agonists, including those of Formulas (I), (II), (III), and (IV), which can induce a STING-mediated immune response and are designed to overcome viral suppression mechanisms, potentially enhancing anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current STING agonists are used to treat diseases mediated by STING, then immune response is activated, but viral suppression mechanisms reduce efficacy
Solution Approach 1:
The patent applies preliminary anti-action by designing STING agonist compounds that are specifically engineered to resist viral suppression mechanisms before the virus can inhibit the immune response. The compounds are structurally optimized to maintain activity despite viral interference, effectively counteracting the suppression in advance.
Solution Approach 2:
The patent employs parameter changes by modifying key structural parameters of STING agonist compounds to improve their efficacy. Specific chemical substitutions and structural optimizations are made to enhance the compounds' ability to activate STING while overcoming viral suppression, thereby changing the effectiveness parameter of the immune response.
2Reliability
If current STING agonists are used for cancer treatment, then some anti-tumor activity is achieved, but poor anti-tumor activity limits therapeutic success
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of STING agonist compounds to enhance their anti-tumor activity. Specific modifications to the molecular structure improve the compounds' ability to induce type I interferon production and activate anti-tumor immune responses, thereby increasing therapeutic success rates.
Solution Approach 2:
The patent employs composite materials by developing STING agonist compounds with complex molecular structures that combine multiple functional groups and moieties. These composite molecular structures synergistically enhance the compounds' anti-tumor activity and overall therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds and conjugates effectively induce STING-dependent type I interferon production and cytokine production, providing a therapeutic approach for treating cancer and other diseases mediated by STING.
Implementation Method 1
These compounds and conjugates effectively induce STING-dependent type I interferon production
Implementation Method 2
induce type I interferons (IFNs) and the production of pro-inflammatory cytokines, such as IL-6, TNF-α, and IFN-γ
Data Source
AI summary
The present disclosure is related to STING agonists, linker-payloads thereof, and conjugates thereof, pharmaceutical compositions thereof, and the use of the agonists, conjugates, and pharmaceutical compositions to induce a STING-mediated immune response and/or for the treatment of diseases and disorders mediated by STING.